Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionAntibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesImmune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruptionVirus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivityEvidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesNeutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection.epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particlesImpact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.Structured treatment interruptions in HIV infection: benefit or disappointment?Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.Acute HIV infection presenting as hemophagocytic syndrome with an unusual serological and virological response to ARTAntigenic conservation and immunogenicity of the HIV coreceptor binding siteAssociation of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linkedPolyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.Humoral immunity to HIV-1: neutralization and beyond.Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.The humoral response to HIV-1: new insights, renewed focus.Candidate antibody-based therapeutics against HIV-1.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infectionNeutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
P2860
Q27489000-046BAC1D-6274-400D-8B42-E0FC764DFD9FQ27643185-55FD2751-78E8-46C9-A034-00859CD2F198Q28766705-59AB2ED0-37E7-4AB7-AB50-02DEF87AF68AQ30408097-617231C8-66CD-4602-AD62-187289C872A4Q33745356-1EE4F5B3-3A6F-48C4-B2D8-B62B3A2D2222Q33843345-13AD49B4-5257-483A-8B24-F3A598096C82Q33987391-52F9A2E7-A0B3-4AAF-813E-9396B269BE84Q34462167-B0022D08-55BE-4AD8-A42D-0D0F457224D1Q34651668-648659EA-A195-40FE-83C9-6D2942915E4FQ34713877-C373B9B1-6F80-4129-800F-3092AFEA3EC0Q34717113-6C6F54BC-9974-4E08-9D77-4C81CA139FB0Q34952914-F93B8564-6BC4-4620-A9DF-0CFA0D807141Q35192660-61838DAA-33FF-4D31-A6EB-6CE943E39FCDQ35208657-5AFB9B81-6CEB-4538-BB27-F3C72A628B5EQ35665765-0CE9B227-BD7F-4706-8443-73BA0274D2ABQ35704086-429BDA7E-AAA1-44C4-BFB8-1252050A30DDQ35785244-68419152-9ECF-4DB6-B587-D9B14F7E6ACBQ35917152-11CC2723-5E57-4A0C-BA0B-DE5F4552BDF2Q35947805-259D034B-F007-4467-B7A7-A942EC1C0841Q35948073-FD8C28EE-86FC-437D-A6BC-989CEED750D7Q36177479-BB7468F1-4837-4D23-B170-5423B4D2D0EEQ36403587-B4085123-1D4F-44CD-9B1B-4D7690D4A9C5Q36421569-101EB654-967B-4D8D-A41B-3B219C1790E7Q36540060-AB5C8AEF-5F0E-4818-9D32-233879E71222Q36541239-1C202B31-E69D-4E9A-82C5-C3DA33C141A9Q36600380-D6E06819-E175-43E5-B09D-CA15770B7177Q36707546-DA386B47-F1D8-449C-8690-36ABBE8F7783Q36863847-54ADF06F-AA63-4F6D-AE08-789E5B6DEC8BQ37051645-49198673-5F45-4797-B0D9-EBF77F1175ADQ37449883-94680C0F-B1F3-4974-A2EB-4EAD4162551CQ37789346-A4004D6B-D258-434A-A51D-67E29564FAD1Q37998496-410350F3-586D-453B-BF47-3CB1F0F4642AQ38977425-3333B2C9-4484-4E1A-A696-FB1F2ED4B05EQ39934862-D762F68B-815E-4DBD-828D-C3F2FEECA8A7Q43750850-04D56D83-E2BA-41C7-8F30-00790B6F0B08Q57226425-FC0F90AB-CC26-4889-B25A-E0416BB005CD
P2860
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Neutralizing antibodies associ ...... ciency virus type 1 infection.
@ast
Neutralizing antibodies associ ...... ciency virus type 1 infection.
@en
type
label
Neutralizing antibodies associ ...... ciency virus type 1 infection.
@ast
Neutralizing antibodies associ ...... ciency virus type 1 infection.
@en
prefLabel
Neutralizing antibodies associ ...... ciency virus type 1 infection.
@ast
Neutralizing antibodies associ ...... ciency virus type 1 infection.
@en
P2093
P2860
P1433
P1476
Neutralizing antibodies associ ...... ciency virus type 1 infection.
@en
P2093
P2860
P304
10200-10207
P356
10.1128/JVI.75.21.10200-10207.2001
P577
2001-11-01T00:00:00Z